Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

Becton Dickinsonâs buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returnsâget the latest Wall St view.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: SeekingAlpha